<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of pulmonary function testing in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of pulmonary function testing in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of pulmonary function testing in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David A Kaminsky, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Meredith C McCormack, MD, MHS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Evaluation of pulmonary function is important in many clinical situations, both when the patient has a history or symptoms suggestive of lung disease and when risk factors for lung disease are present, such as occupational exposure to agents with known lung toxicity [<a href="#rid1">1</a>].</p><p>The European Respiratory Society and the American Thoracic Society have published guidelines for the measurement and interpretation of pulmonary function tests (PFTs) [<a href="#rid2">2-10</a>].</p><p>An overview of pulmonary function testing will be presented here, summarizing the types of PFTs and their indications. Specific aspects of pulmonary function testing are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/6968.html" rel="external">"Office spirometry"</a> and  <a class="medical medical_review" href="/d/html/6971.html" rel="external">"Selecting reference values for pulmonary function tests"</a> and  <a class="medical medical_review" href="/d/html/6972.html" rel="external">"Diffusing capacity for carbon monoxide"</a> and  <a class="medical medical_review" href="/d/html/569.html" rel="external">"Pulmonary function testing in asthma"</a> and  <a class="medical medical_review" href="/d/html/525.html" rel="external">"Bronchoprovocation testing"</a> and  <a class="medical medical_review" href="/d/html/5735.html" rel="external">"Overview of pulmonary function testing in children"</a>.)</p><p class="headingAnchor" id="H2470159598"><span class="h1">ADVICE RELATED TO COVID-19 PANDEMIC</span><span class="headingEndMark"> — </span>Spirometry and other pulmonary function test (PFT) maneuvers can promote coughing and aerosol generation and could lead to spread of coronavirus disease 2019 (COVID-19; SARS-CoV-2) by infected patients. It is difficult to screen patients for active COVID-19 infection, particularly those with underlying respiratory symptoms, and infected but asymptomatic patients can shed the virus. Thus, we agree with expert recommendations that spirometry and other PFTs be limited to patients in whom results are essential to immediate management decisions [<a href="#rid11">11</a>]. Use of nebulizers to administer bronchodilators or <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> for testing should be avoided.</p><p>Measures to prevent spread of COVID-19 should include hand hygiene and personal protective equipment (PPE; gloves, gown, face mask and shield) for staff and anyone else in the testing space (eg, interpreters). N95 masks or powered air purifying respirators (PAPR) are preferred over surgical masks. Patients should be brought to a testing room using an approach that avoids queuing or grouping individuals in a waiting area.</p><p>PFT equipment should be fitted with single-use mouthpieces and disposable in-line bacterial and viral filters [<a href="#rid12">12-14</a>]. Enhanced cleaning of the testing area should be performed between patients. Performance of PFTs can generate aerosol particles, potentially carrying infectious virus, even when a filter is used [<a href="#rid15">15</a>]. Thus, it is preferred that negative pressure rooms with at least six air exchanges per hour be used. Recognizing that the time needed for optimal clearance of aerosol particles varies among laboratories, closure between patients is recommended for 20 minutes to 3 hours (depending on ventilation of the particular space) to enable clearance of respiratory aerosols [<a href="#rid12">12-14</a>]. A consensus statement has been published for reference [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H2"><span class="h1">PULMONARY FUNCTION TESTS</span><span class="headingEndMark"> — </span>The major types of pulmonary function tests (PFTs) are spirometry, spirometry before and after a bronchodilator, lung volumes, and quantitation of diffusing capacity for carbon monoxide. Additional PFTs, such as measurement of maximal respiratory pressures, flow-volume loops, submaximal exercise testing, and bronchoprovocation challenge, are useful in specific clinical circumstances  (<a class="graphic graphic_table graphicRef106178" href="/d/graphic/106178.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Holding bronchodilator medications</strong> – In preparation for PFTs, bronchodilator medications are typically held so that bronchodilator response can be assessed after baseline spirometry. As examples, short-acting inhaled beta agonists (eg, <a class="drug drug_general" data-topicid="9396" href="/d/drug information/9396.html" rel="external">albuterol</a>, salbutamol) should not be used for four to six hours prior to testing [<a href="#rid6">6</a>]. The short-acting muscarinic antagonist <a class="drug drug_general" data-topicid="8570" href="/d/drug information/8570.html" rel="external">ipratropium</a> should be held for 12 hours. Long-acting beta agonist bronchodilators (eg, <a class="drug drug_general" data-topicid="9875" href="/d/drug information/9875.html" rel="external">salmeterol</a>, <a class="drug drug_general" data-topicid="8946" href="/d/drug information/8946.html" rel="external">formoterol</a>) should be held for 24 hours prior to testing. The ultra-long-acting beta agonists (eg, <a class="drug drug_general" data-topicid="16792" href="/d/drug information/16792.html" rel="external">indacaterol</a>, <a class="drug drug_general" data-topicid="96482" href="/d/drug information/96482.html" rel="external">olodaterol</a>, vilanterol) should be held for 36 hours, and the long-acting muscarinic antagonists (also called anticholinergic agents) <a class="drug drug_general" data-topicid="8496" href="/d/drug information/8496.html" rel="external">glycopyrrolate</a> (glycopyrronium), <a class="drug drug_general" data-topicid="10300" href="/d/drug information/10300.html" rel="external">tiotropium</a>, <a class="drug drug_general" data-topicid="86043" href="/d/drug information/86043.html" rel="external">aclidinium</a>, and <a class="drug drug_general" data-topicid="95147" href="/d/drug information/95147.html" rel="external">umeclidinium</a> should be held for 36 to 48 hours.</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Spirometry</span><span class="headingEndMark"> — </span>Spirometry, the most readily available and useful pulmonary function test, measures the volume of air exhaled at specific time points during a forceful and complete exhalation after a maximal inhalation [<a href="#rid6">6</a>]. The total exhaled volume, known as the forced vital capacity (FVC), the volume exhaled in the first second, known as the forced expiratory volume in one second (FEV<sub>1</sub>), and their ratio (FEV<sub>1</sub>/FVC) are the most important variables reported [<a href="#rid17">17</a>]. The test takes 10 to 15 minutes and carries minimal risk (eg, rarely syncope). The techniques for performing spirometry and interpretation of results are described separately. (See  <a class="medical medical_review" href="/d/html/6968.html" rel="external">"Office spirometry"</a> and  <a class="medical medical_review" href="/d/html/1465.html" rel="external">"Flow-volume loops"</a>.)</p><p>Spirometry is a key diagnostic test for asthma and chronic obstructive pulmonary disease (COPD) when performed before and after bronchodilator and is useful to assess for asthma or other causes of airflow obstruction in the evaluation of chronic cough. It is also used to monitor a broad spectrum of respiratory diseases, including asthma, COPD, interstitial lung disease, and neuromuscular diseases affecting respiratory muscles.</p><p>The slow vital capacity (SVC) can be measured as the maximal amount of air exhaled in a relaxed expiration from full inspiration to residual volume; exhalation should be terminated after 15 seconds [<a href="#rid6">6</a>]. The SVC may be a useful measurement when the FVC is reduced and airway obstruction is present. Slow exhalation results in a lesser degree of airway narrowing, and the patient may produce a larger, even normal vital capacity. In contrast, the vital capacity with restrictive disease is reduced during both slow and fast maneuvers. Thus, if the slow or forced vital capacity is within the normal range, it is generally unnecessary to measure static lung volumes (residual volume and total lung capacity) [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H281210450"><span class="h3">Post-bronchodilator</span><span class="headingEndMark"> — </span>Performance of spirometry before and after bronchodilator is used to determine the degree of bronchodilator responsiveness. Administration of <a class="drug drug_general" data-topicid="9396" href="/d/drug information/9396.html" rel="external">albuterol</a> by metered-dose inhaler (MDI) is indicated if baseline spirometry demonstrates airway obstruction or if one suspects asthma or COPD. Albuterol or an equivalent short-acting beta agonist is administered by MDI with a spacer or chamber device  (<a class="graphic graphic_picture graphicRef74135" href="/d/graphic/74135.html" rel="external">picture 1</a>); proper MDI technique is important to prevent false negative results [<a href="#rid6">6</a>]. Bronchodilator may also be administered by nebulizer according to standard local practice. Spirometry should be repeated 10 to 15 minutes after administration of a bronchodilator. (See  <a class="medical medical_review" href="/d/html/559.html" rel="external">"The use of inhaler devices in adults"</a>.)</p><p>The European Respiratory Society/American Thoracic Society(ERS/ATS) interpretation standards recommend that a significant bronchodilator response be defined by a greater than or equal to increase in FEV<sub>1</sub> or FVC by 10 percent of their respective predicted values [<a href="#rid3">3</a>]. This is in contrast to the prior definition of an increase in the FEV<sub>1</sub> or FVC of more than 12 percent and greater than 0.2 L [<a href="#rid2">2</a>]. This new definition is thought to be more accurate in terms of avoiding age and size bias [<a href="#rid19">19</a>], is based on the upper limit of normal from worldwide data [<a href="#rid20">20</a>], and is also associated with the important clinical outcome of mortality [<a href="#rid19">19</a>].</p><p>In patients with asthma, bronchodilator administration often results in improvement, and in some patients with asthma, post-bronchodilator testing may improve to normal spirometry values. Among patients with COPD, administration of bronchodilator sometimes leads to a significant change in FEV<sub>1</sub> or FVC [<a href="#rid21">21</a>], but reversal to normal spirometry makes COPD less likely [<a href="#rid22">22</a>]. Bronchodilators may also lead to improvement in flow in the small airways and a reduction in air trapping. While criteria for assessment of reduced air trapping have not been formalized, an increase in inspiratory capacity (IC) and a decrease in functional residual capacity (FRC) are thought to reflect this response. (See <a class="local">'Lung volumes'</a> below.)</p><p>Sometimes, patients will note subjective improvements in their breathing after bronchodilator inhalation, but without associated changes in FVC or FEV<sub>1</sub> [<a href="#rid23">23</a>]. It is thought that increased airflow within the tidal volume range, but not during deep inhalation, may account for this discrepancy. Deep inhalations may be associated with airway narrowing, which may offset the measured bronchodilator response. Thus, the lack of an acute bronchodilator response on spirometry should not preclude a therapeutic trial of bronchodilators and/or inhaled glucocorticoids, with reassessment of clinical status and change in FEV<sub>1</sub> at the end of that time [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H4"><span class="h3">Flow-volume loop</span><span class="headingEndMark"> — </span>Flow-volume loops, which include forced inspiratory and expiratory maneuvers, are always useful but especially whenever stridor is heard over the neck and when evaluating unexplained dyspnea. Airway obstruction located in the pharynx, larynx, or trachea (upper airways) is usually impossible to detect from standard expiratory FVC maneuvers. Reproducible forced inspiratory vital capacity (FIVC) maneuvers may detect variable extrathoracic upper airway obstruction [<a href="#rid24">24</a>], as can be seen with vocal fold paralysis or dysfunction, which causes a characteristic limitation of flow (plateau) during forced inhalation but little if any obstruction during exhalation  (<a class="graphic graphic_figure graphicRef76811" href="/d/graphic/76811.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/1465.html" rel="external">"Flow-volume loops"</a> and  <a class="medical medical_review" href="/d/html/523.html" rel="external">"Inducible laryngeal obstruction (paradoxical vocal fold motion)", section on 'Pulmonary function tests'</a>.)</p><p>Less commonly, a fixed upper airway obstruction (UAO) (eg, tracheal stenosis) causes flow limitation during both forced inhalation and forced exhalation maneuvers  (<a class="graphic graphic_figure graphicRef76811" href="/d/graphic/76811.html" rel="external">figure 1</a>). However, the flow-volume loop is not sensitive for detecting a fixed UAO, since the tracheal lumen is often reduced to less than 1 cm before a plateau is recognized. Poor technique or effort can mimic the flow-volume loop shapes of upper airway obstruction but are usually excluded when three or more maneuvers are seen to be repeatable.</p><p class="headingAnchor" id="H2273434927"><span class="h3">Bronchoprovocation challenge</span><span class="headingEndMark"> — </span>Spirometry is used to assess the airway hyperresponsiveness to a variety of bronchoprovocation challenges, such as <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a>, <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a>, exercise, and isocapnic hyperpnea. Bronchoprovocation challenge is discussed separately. (See  <a class="medical medical_review" href="/d/html/525.html" rel="external">"Bronchoprovocation testing"</a>.)</p><p class="headingAnchor" id="H2273434933"><span class="h3">Supine and sitting spirometry</span><span class="headingEndMark"> — </span>To evaluate respiratory muscle weakness, spirometry can be obtained with the patient supine and sitting. Diaphragmatic weakness is suggested by a decrease in the supine vital capacity (VC) &gt;10 percent. Unilateral diaphragmatic paralysis is usually associated with a decrease in VC of 15 to 25 percent; bilateral diaphragmatic paralysis can be associated with a decrease in supine VC approaching 50 percent. (See  <a class="medical medical_review" href="/d/html/5115.html" rel="external">"Diagnostic evaluation of adults with bilateral diaphragm paralysis", section on 'Pulmonary function tests'</a> and  <a class="medical medical_review" href="/d/html/16185.html" rel="external">"Diagnosis and management of nontraumatic unilateral diaphragmatic paralysis (complete or partial) in adults", section on 'Pulmonary function testing'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Lung volumes</span><span class="headingEndMark"> — </span>Measurement of lung volumes is important when spirometry shows a decreased forced vital capacity. Body plethysmography is the gold standard for measurement of lung volumes, particularly in the setting of airflow obstruction [<a href="#rid5">5</a>], although lung volumes can be overestimated in the situation of severe airflow obstruction [<a href="#rid25">25</a>]. Alternative methods include helium dilution, nitrogen washout, and measurements based on chest imaging. Helium dilution and nitrogen washout may underestimate lung volume in patients with moderate to severe COPD because they do not access under- or nonventilated areas.</p><p>Measurements of total lung capacity (TLC) using the chest radiograph or high-resolution computed tomography (HRCT) correlate within 15 percent of those obtained by body plethysmography [<a href="#rid5">5,26</a>]. Since the TLC is equivalent to the amount of air seen in the lungs on a chest radiograph taken at maximal inspiration, it is important that the subject inhales maximally as the image is created.</p><p>Common lung volume measurements include vital capacity, total lung capacity, functional residual capacity, and residual volume. By convention, the term capacity is used for compartments composed of two or more volumes. The relationships among the lung volumes and capacities are shown in the figure  (<a class="graphic graphic_figure graphicRef55440" href="/d/graphic/55440.html" rel="external">figure 2</a>) and listed below:</p><p class="bulletIndent1"><span class="glyph">●</span>Vital capacity (VC): maximum volume exhaled after maximum inspiration; can be measured during forced exhalation (FVC) or slow exhalation (SVC)</p><p class="bulletIndent1"><span class="glyph">●</span>Functional residual capacity (FRC): volume of air remaining in chest at the end of a tidal volume breath</p><p class="bulletIndent1"><span class="glyph">●</span>Residual volume (RV): volume of air remaining in chest after maximal exhalation</p><p class="bulletIndent1"><span class="glyph">●</span>Expiratory reserve volume (ERV): volume of air exhaled from end-tidal volume (FRC) to point of maximal exhalation (RV), so RV plus ERV = FRC</p><p class="bulletIndent1"><span class="glyph">●</span>Inspiratory capacity (IC): maximum inspiration from end-tidal volume (FRC) to total lung capacity</p><p class="bulletIndent1"><span class="glyph">●</span>Inspiratory reserve volume (IRV): volume of air inhaled during tidal breathing from end-inhalation to total lung capacity</p><p class="bulletIndent1"><span class="glyph">●</span>Total lung capacity (TLC): volume of air in lungs at end of maximal inspiration (usually calculated by RV plus VC or FRC plus IC)</p><p></p><p>A schema for the interpretation of PFT results is provided in the algorithm  (<a class="graphic graphic_algorithm graphicRef96311" href="/d/graphic/96311.html" rel="external">algorithm 1</a>) [<a href="#rid3">3</a>]. TLC is the key lung volume for determining restriction, defined as a TLC value less than the 5<sup>th</sup> percentile of the predicted normal range (z-score &lt;-1.645; roughly and imperfectly approximated by values less than 80 percent of predicted); a reduced VC alone is not sufficient evidence of restriction because it can be caused by air trapping due to severe obstruction, neuromuscular weakness, or suboptimal effort [<a href="#rid2">2</a>].</p><p>Air trapping is indicated when the RV or RV/TLC is increased (&gt;upper limit of normal [ULN]); hyperinflation is indicated when the FRC and/or TLC are increased (&gt;ULN). Thus, in the setting of COPD with obstruction on spirometry and a low vital capacity, measurement of lung volumes can help determine if there is a superimposed restrictive disorder or if VC is decreased due to air trapping or hyperinflation.</p><p>The combination of an FEV<sub>1</sub>/FVC and TLC both less than the fifth percentile lower limit of normal (LLN) is considered a mixed defect [<a href="#rid3">3</a>]. The combination of a normal FEV<sub>1</sub>/FVC and a normal TLC and a low FEV<sub>1</sub> or FVC is considered the nonspecific pattern [<a href="#rid27">27</a>]. The pattern in which the FVC is disproportionately reduced relative to TLC has been described as the complex restrictive pattern [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Maximal respiratory pressures</span><span class="headingEndMark"> — </span>Measurement of maximal inspiratory and expiratory pressures is indicated whenever there is an unexplained decrease in vital capacity or respiratory muscle weakness is suspected clinically. Maximal inspiratory pressure (MIP), measured near RV, is the maximal pressure that can be produced by the patient trying to inhale through a blocked mouthpiece after a full exhalation. Maximal expiratory pressure (MEP) is the maximal pressure measured during forced expiration (with cheeks bulging) through a blocked mouthpiece after a nearly full inhalation to TLC. Repeated measurements of MIP and MEP are useful in following the course of patients with neuromuscular disorders. The slow vital capacity may also be followed, but it is less specific and usually less sensitive. (See  <a class="medical medical_review" href="/d/html/6965.html" rel="external">"Tests of respiratory muscle strength"</a>.)</p><p>Maximal inspiratory and expiratory pressures are easily measured using a simple mechanical pressure gauge connected to a mouthpiece. MIP measures the ability of the diaphragm and the other respiratory muscles to generate inspiratory force, reflected by a negative airway pressure. The average MIP and MEP for adult men are -100 and +170 cm H<sub>2</sub>O, respectively, while the corresponding values for adult women are approximately -70 and +110 cm H<sub>2</sub>O, respectively [<a href="#rid29">29,30</a>]. The LLN range is approximately two-thirds of these values. (See  <a class="medical medical_review" href="/d/html/6965.html" rel="external">"Tests of respiratory muscle strength", section on 'Interpretation (PImax, PEmax, SNIP)'</a>.)</p><p class="headingAnchor" id="H91879305"><span class="h2">Diffusing capacity</span><span class="headingEndMark"> — </span>Measurement of the single-breath diffusing capacity for carbon monoxide (DLCO; also known as transfer factor or TLCO) is quick, safe, and useful in the evaluation of restrictive and obstructive lung disease, as well as pulmonary vascular disease. The technique and interpretation are discussed separately [<a href="#rid3">3,7,31</a>]. (See  <a class="medical medical_review" href="/d/html/6972.html" rel="external">"Diffusing capacity for carbon monoxide", section on 'Methodology'</a>.)</p><p>Interpretation of abnormal DLCO values differs based on any underlying concomitant pulmonary process  (<a class="graphic graphic_table graphicRef73588" href="/d/graphic/73588.html" rel="external">table 2</a>). In the setting of restrictive disease, the diffusing capacity helps distinguish between intrinsic lung disease, in which DLCO is usually reduced, and other causes of restriction due to reduced lung volume, in which DLCO is often normal. In the setting of obstructive disease, the DLCO helps distinguish between emphysema, in which it is usually reduced, and other causes of chronic airway obstruction, like asthma or chronic bronchitis, where it is usually normal. The DLCO is also used in the assessment of pulmonary vascular disease (eg, thromboembolic disease, pulmonary hypertension), which typically causes a reduction in DLCO in the absence of significant restriction or obstruction. (See <a class="local">'Pulmonary vascular disease'</a> below and  <a class="medical medical_review" href="/d/html/6972.html" rel="external">"Diffusing capacity for carbon monoxide"</a>.)</p><p class="headingAnchor" id="H2054965755"><span class="h1">GRADING PHYSIOLOGIC IMPAIRMENT</span><span class="headingEndMark"> — </span>ERS/ATS interpretation standards emphasize that PFTs can only assess physiologic diagnoses and not clinical ones. Similarly, the severity of lung disease cannot be determined by PFTs, only the degree of physiologic impairment. Physiologic impairment should preferably be assessed based on z-score, instead of percent predicted, because this scale helps avoid age, sex, and height bias and is closely associated with important clinical outcomes [<a href="#rid32">32,33</a>].</p><p>FEV<sub>1</sub> is the primary measure used to grade the physiologic severity of obstructive or mixed obstructive-restrictive processes  (<a class="graphic graphic_algorithm graphicRef139645" href="/d/graphic/139645.html" rel="external">algorithm 2</a>). We prefer to use TLC z-score to grade severity of restriction; however, FEV<sub>1</sub> may be used as an alternative to grade previously confirmed restriction if lung volumes or z-scores are not available [<a href="#rid2">2</a>]. When using z-scores, physiologic impairment severity (by FEV<sub>1</sub>, TLC, or DLCO) is graded as follows:</p><p class="bulletIndent2"><span class="glyph">•</span>Abnormally elevated – Z-score &gt;1.645</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normal – Z-score of -1.645 to 1.645</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In the setting of established obstruction (a reduced FEV<sub>1</sub>/FVC), an FEV<sub>1</sub> in the normal range still indicates a mild obstructive deficit.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mildly impaired – Z-score of -1.65 to -2.5</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moderately impaired – Z-score of -2.5 to -4</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severely impaired – Z-score &lt;-4</p><p></p><p>A grading approach using percent of predicted normal values can be used as a nonpreferred alternative when z-scores are not available  (<a class="graphic graphic_algorithm graphicRef139645" href="/d/graphic/139645.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef60743" href="/d/graphic/60743.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H3929674503"><span class="h1">OTHER TESTING</span></p><p class="headingAnchor" id="H26338868"><span class="h2">Submaximal exercise testing</span><span class="headingEndMark"> — </span>Submaximal exercise testing is often conducted in the pulmonary function laboratory and does not require the resources needed for a maximal cardiopulmonary exercise test [<a href="#rid4">4,34</a>]. Three commonly used submaximal tests are the six-minute walk test, the incremental shuttle walk test, and the endurance shuttle walk test. Cardiopulmonary exercise testing is discussed separately. (See  <a class="medical medical_review" href="/d/html/3465.html" rel="external">"Cardiopulmonary exercise testing in cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H13496651"><span class="h3">Six-minute walk test</span><span class="headingEndMark"> — </span>The six-minute walk test (6MWT) is a good index of physical function and therapeutic response in patients with chronic lung disease, such as COPD, pulmonary fibrosis, or pulmonary arterial hypertension [<a href="#rid4">4,34-37</a>]. The test should be performed according to standard methods  (<a class="graphic graphic_table graphicRef90285" href="/d/graphic/90285.html" rel="external">table 4</a>) [<a href="#rid4">4</a>], including a practice walk to orient the patient to the procedure. During a 6MWT, healthy subjects can typically walk 400 to 700 m [<a href="#rid35">35,38</a>]. In addition to total distance walked, the magnitude of desaturation and timing of heart rate recovery have been associated with clinical outcomes.</p><p>Studies to understand meaningful changes in six-minute walk distances have been conducted in several disease states. While there is some variability based on methods and study population, the available evidence suggests an improvement of approximately 30 m in distance walked is the minimally important difference (MID) [<a href="#rid36">36,39-46</a>]. While pulse oxygen saturation and heart rate are recorded before and after the test, the 6MWT is not designed to be an oxygen titration study, and a separate study should be performed to determine supplemental oxygen needs.</p><p class="headingAnchor" id="H390637296"><span class="h3">Incremental shuttle walk test</span><span class="headingEndMark"> — </span>The incremental shuttle walk test (ISWT) is a 12-level test in which the subject walks at a progressively increasing speed for 12 minutes over a 10-meter course, where each 10 m trip between cones is a "shuttle" [<a href="#rid47">47-50</a>]. Heart rate can be monitored by pulse oximetry or telemetry [<a href="#rid50">50</a>]. The walking speed increases every minute from an initial 0.5 m/sec to 2.37 m/sec at level 12. The test is stopped when the subject is limited by dyspnea or heart rate (&gt;85 percent predicted maximum), is unable to maintain the required speed, or completes the 12 levels. The primary outcome is the distance covered, which is calculated from the number of completed shuttles.</p><p>The distance walked in the ISWT depends on factors such as age, body mass index, FEV<sub>1</sub>, quadriceps strength, and activity status, but reliable predictive equations for normal values have not been developed [<a href="#rid49">49</a>]. As a rough estimate, healthy men were able to achieve the following ISWT distances: age 40 to 49 years, 824 m; 50 to 59 years, 788 m; 60 to 69 years, 699 m; and 70 years and older, 633 m [<a href="#rid49">49,51</a>].</p><p>The validity of the ISWT was assessed in a systematic review, which found that the ISWT distance correlated with peak oxygen uptake in subjects with COPD or cardiac disease (r values ranged from 0.67 to 0.95) [<a href="#rid47">47</a>]. In addition, the ISWT distance walked was responsive to pulmonary rehabilitation and bronchodilator administration. The minimal clinically important distance in the ISWT in patients with COPD was 48 meters.</p><p>The ISWT is sometimes used as a screening test in the preoperative assessment of patients for lung resection for lung cancer. An ISWT distance greater than 400 meters has been associated with a maximum oxygen uptake (VO<sub>2</sub> max) ≥15 mL/kg per minute [<a href="#rid52">52</a>], indicating sufficient pulmonary reserve to tolerate lung resection surgery. (See  <a class="medical medical_review" href="/d/html/6973.html" rel="external">"Preoperative physiologic pulmonary evaluation for lung resection", section on 'Integrated cardiopulmonary exercise testing'</a>.)</p><p class="headingAnchor" id="H390637290"><span class="h3">Endurance shuttle walk test</span><span class="headingEndMark"> — </span>In the endurance shuttle walk test (ESWT), the subject walks at a constant speed between cones that are 10 meters apart [<a href="#rid53">53</a>]. The subject's speed is selected to be approximately 85 percent of the maximal capacity measured from the ISWT, so an ISWT is needed before the first ESWT [<a href="#rid54">54</a>]. During the ESWT, a pre-recorded audio signal is used to communicate the target speed to the subject. Subjects walk until they are too breathless, too tired, or no longer able to maintain the pace. Generally, the test is stopped at 20 minutes, if the subject is still walking at that time. The primary measure is total time walked with a minimal important difference of 65 seconds or 85 meters following bronchodilation.</p><p class="headingAnchor" id="H9"><span class="h2">Pulse oxygen saturation</span><span class="headingEndMark"> — </span>Assessment of oxygen saturation can be used to identify a gas transfer defect and to titrate the amount of oxygen needed to maintain adequate oxygenation. (See  <a class="medical medical_review" href="/d/html/1612.html" rel="external">"Pulse oximetry"</a> and  <a class="medical medical_review" href="/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy"</a>.)</p><p>A clear consensus has not been reached about what value for resting oximetry differentiates normal and abnormal. At sea level, values for pulse oxygen saturation (SpO<sub>2</sub>) ≤95 percent are considered abnormal, although a decrease to 96 percent in a patient who has a previous value of 100 percent could be abnormal. Exertional decreases in SpO<sub>2</sub> ≥5 percentage points are also considered abnormal. A value of SpO<sub>2</sub> ≤88 percent is generally an indication for supplemental oxygen, although the benefits of supplemental oxygen in patients with normal resting saturations and exertional decreases to ≤88 percent are unclear [<a href="#rid55">55</a>]. Confirmation of abnormal values with arterial blood gas (ABG) measurements may be indicated.</p><p class="headingAnchor" id="H91879345"><span class="h2">Arterial blood gases</span><span class="headingEndMark"> — </span>ABGs are a helpful adjunct to pulmonary function testing in selected patients. The primary role of measuring ABGs in stable outpatients is to confirm hypercapnia when it is suspected on the basis of clinical history (eg, respiratory muscle weakness, advanced COPD), an elevated serum bicarbonate level, and/or chronic hypoxemia. ABGs also provide a more accurate assessment of the severity of gas exchange impairment in patients who have low normal pulse oxygen saturation (eg, &lt;92 percent) [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/d/html/1648.html" rel="external">"Arterial blood gases"</a> and  <a class="medical medical_review" href="/d/html/16991.html" rel="external">"Venous blood gases and other alternatives to arterial blood gases"</a> and  <a class="medical medical_review" href="/d/html/2352.html" rel="external">"Simple and mixed acid-base disorders"</a>.)</p><p class="headingAnchor" id="H335493654"><span class="h1">CLINICAL USE OF PULMONARY FUNCTION TESTS</span><span class="headingEndMark"> — </span>Pulmonary function testing is useful for evaluation of a variety of forms of lung disease or for assessing the presence of disease in a patient with known risk factors, such as certain rheumatic diseases and occupational exposure to agents with known lung toxicity. The American Thoracic Society advises using a standard report format to improve communication and understanding of test results  (<a class="graphic graphic_figure graphicRef116692" href="/d/graphic/116692.html" rel="external">figure 3</a>) [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Indications for pulmonary function tests (PFTs) include  (<a class="graphic graphic_table graphicRef106178" href="/d/graphic/106178.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of symptoms such as chronic persistent cough, wheezing, dyspnea, and exertional cough or chest pain</p><p class="bulletIndent1"><span class="glyph">●</span>Objective assessment of bronchodilator therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of effects of exposure to dusts or chemicals at work</p><p class="bulletIndent1"><span class="glyph">●</span>Risk evaluation of patients prior to thoracic or upper abdominal surgery</p><p class="bulletIndent1"><span class="glyph">●</span>Objective assessment of respiratory impairment</p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring disease course and response to therapy</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Chronic dyspnea</span><span class="headingEndMark"> — </span>Many lung diseases begin slowly and insidiously and finally manifest themselves with the nonspecific symptom of dyspnea on exertion. PFTs are an essential part of the workup of such patients. In the outpatient setting, in which several days to weeks are available to make the diagnosis, a cost efficient method of ordering PFTs is to start with spirometry before and after a bronchodilator and then order further tests in a stepwise fashion to refine the diagnosis  (<a class="graphic graphic_algorithm graphicRef67095" href="/d/graphic/67095.html" rel="external">algorithm 3</a>). (See  <a class="medical medical_review" href="/d/html/1436.html" rel="external">"Approach to the patient with dyspnea"</a>.)</p><p>When a diagnosis is needed within a day or two, a full set of PFTs may be ordered, often including spirometry before and after (pre- and post-) bronchodilator therapy, static lung volumes, and diffusing capacity. If the cause of dyspnea on exertion remains uncertain after these tests have been performed, cardiopulmonary exercise testing should be considered.</p><p class="headingAnchor" id="H12"><span class="h2">Asthma</span><span class="headingEndMark"> — </span>Spirometry before and after a bronchodilator is indicated during the initial workup of patients suspected of having asthma  (<a class="graphic graphic_algorithm graphicRef67095" href="/d/graphic/67095.html" rel="external">algorithm 3</a>). Spirometry is also indicated during most follow-up office visits to provide an objective measure of asthma control [<a href="#rid57">57</a>]. (See <a class="local">'Spirometry'</a> above and  <a class="medical medical_review" href="/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/569.html" rel="external">"Pulmonary function testing in asthma"</a>.)</p><p>Cough or chest tightness with exercise or exposure to cold air, dusts, or fumes suggests bronchial hyperresponsiveness (BHR). However, BHR may not be detected by pre- and post-bronchodilator spirometry if the patient is asymptomatic at the time of evaluation. Commonly, the patient is asked to return for retesting when symptoms occur; however, this delays the diagnosis and may be impractical. Inhalation challenge testing can increase or decrease the pretest probability of asthma in less than an hour. (See  <a class="medical medical_review" href="/d/html/525.html" rel="external">"Bronchoprovocation testing"</a> and  <a class="medical medical_review" href="/d/html/533.html" rel="external">"Exercise-induced bronchoconstriction"</a>.)</p><p>An alternative to inhalation challenge testing for the detection of airway hyperreactivity is measurement of airway lability for two weeks in the patient's own environment, using ambulatory monitoring of peak flow. Children with asthma (not controlled by medication) typically demonstrate peak flow lability (amplitude/mean) in excess of 30 percent, while adults with active asthma have peak expiratory flow (PEF) lability greater than 20 percent. (See  <a class="medical medical_review" href="/d/html/568.html" rel="external">"Peak expiratory flow monitoring in asthma"</a>.)</p><p>A forced inspiratory maneuver performed as part of a flow-volume loop may be useful in detecting inducible laryngeal obstruction, also known as vocal fold (or cord) dysfunction or paradoxical vocal fold motion, in patients with a presentation suggestive of asthma who do not respond appropriately to asthma therapy. (See  <a class="medical medical_review" href="/d/html/563.html" rel="external">"Evaluation of wheezing illnesses other than asthma in adults"</a> and  <a class="medical medical_review" href="/d/html/523.html" rel="external">"Inducible laryngeal obstruction (paradoxical vocal fold motion)"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Chronic obstructive pulmonary disease</span><span class="headingEndMark"> — </span>Spirometry before and after an inhaled bronchodilator administration is the best method to detect or confirm airways obstruction in smokers with respiratory symptoms  (<a class="graphic graphic_algorithm graphicRef67095" href="/d/graphic/67095.html" rel="external">algorithm 3</a>) [<a href="#rid58">58,59</a>].</p><p>In patients with chronic obstructive pulmonary disease (COPD), the forced expiratory volume in one second/forced vital capacity (FEV<sub>1</sub>/FVC) ratio and the FEV<sub>1</sub> are decreased. Repeating spirometry after bronchodilator enables assessment of irreversible airflow limitation, which is needed for the diagnosis of COPD. Traditionally, values below 70 percent for the FEV<sub>1</sub>/FVC ratio and below 80 percent predicted for the FEV<sub>1</sub> were used to define airflow obstruction. However, several studies suggest that use of fixed thresholds leads to misclassification, particularly in older adults where COPD can be falsely diagnosed [<a href="#rid60">60,61</a>]. Using the fifth percentile lower limit of normal (LLN), or equivalently a z-score &lt;­1.645, instead of a fixed value avoids this misdiagnosis of COPD in older adults, although some argue that the fixed ratio of 0.7 has more clinical relevance [<a href="#rid62">62</a>]. The value for the post-bronchodilator FEV<sub>1</sub> is used to assess COPD severity. (See <a class="local">'Post-bronchodilator'</a> above and  <a class="medical medical_review" href="/d/html/6968.html" rel="external">"Office spirometry", section on 'Ratio of FEV1/FVC'</a> and  <a class="medical medical_review" href="/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging", section on 'Assessment of severity and staging'</a>.)</p><p>The FEV<sub>1</sub>/FVC ratio is typically the value reported and used to assess the presence of airflow obstruction, although FEV<sub>1</sub>/slow vital capacity (FEV1/SVC) can also be used and may be more sensitive in detecting airflow obstruction [<a href="#rid3">3</a>].</p><p>The gold standard for measurement of total lung capacity (TLC), particularly in the setting of significant airflow obstruction, is body plethysmography. Other methods, such as helium dilution and nitrogen washout, may underestimate the TLC in patients with moderate to severe COPD. As noted above, lung volume measurement may identify air trapping or hyperinflation caused by airflow limitation. A concomitant restrictive ventilatory defect is detected in less than 10 percent of patients with a reduced FVC [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging"</a>.)</p><p>Once the diagnosis of COPD is established, the course and response to therapy may be followed by observing changes in the FEV<sub>1</sub>, as was done in the multicenter Lung Health Study [<a href="#rid64">64</a>]. Continued smoking in a patient with airways obstruction often results in an abnormally rapid decline in FEV<sub>1</sub> (90 to 150 mL/year). On the other hand, smoking cessation often results in an increase in FEV<sub>1</sub> during the first year, followed by a nearly normal rate of FEV<sub>1</sub> decline (20 to 30 mL/year) [<a href="#rid65">65</a>]. Both a low FEV<sub>1</sub> and chronic mucus hypersecretion are predictors of hospitalization due to COPD [<a href="#rid66">66</a>].</p><p>Once the airways obstruction due to COPD has become very severe, with an FEV<sub>1</sub> z-score of &lt;-4, changes from visit to visit are usually within the error of the measurement (0.2 L). In this circumstance, measurements of pulse oxygen saturation (SpO<sub>2</sub>) during exercise and distance walked during six minutes may be more clinically meaningful for evaluating disease progression or therapeutic response than are changes in spirometry values [<a href="#rid4">4,67</a>].</p><p>Measurement of the diffusing capacity for carbon monoxide (DLCO) helps to distinguish between emphysema and other causes of chronic airway obstruction and has been shown to improve assessment of patients with COPD [<a href="#rid68">68</a>]. As an example, emphysema lowers the DLCO, obstructive chronic bronchitis does not affect the DLCO, and asthma sometimes increases the DLCO. Changes in the DLCO in patients with established, smoking-related COPD are probably not clinically useful during follow-up visits, unless dyspnea suddenly worsens without an obvious cause. (See  <a class="medical medical_review" href="/d/html/6972.html" rel="external">"Diffusing capacity for carbon monoxide"</a>.)</p><p class="headingAnchor" id="H2818134973"><span class="h2">Upper airway obstruction</span><span class="headingEndMark"> — </span>Intrathoracic upper airway obstruction can be either fixed (eg, due to an airway stricture or goiter) or variable (eg, tracheomalacia, tracheal tumors). Fixed intrathoracic obstruction is associated with reduced airflow during expiration and inspiration with flattening of both limbs on the flow-volume loop  (<a class="graphic graphic_figure graphicRef76811" href="/d/graphic/76811.html" rel="external">figure 1</a>). Variable intrathoracic obstruction is associated with flow limitation during forced expiration, but not during inhalation. (See  <a class="medical medical_review" href="/d/html/1465.html" rel="external">"Flow-volume loops"</a>.)</p><p>Extrathoracic upper airway obstruction can also be fixed or variable. When fixed, the pattern looks like fixed intrathoracic upper airway obstruction and flow is limited during inspiration and expiration. When variable, the inspiratory portion of the loop shows flow limitation and flattening  (<a class="graphic graphic_figure graphicRef76811" href="/d/graphic/76811.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/1465.html" rel="external">"Flow-volume loops", section on 'Abnormal inspiratory loop'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Restrictive ventilatory defect</span><span class="headingEndMark"> — </span>The many disorders that cause reduction of lung volumes (restriction) may be divided into three groups:</p><p class="bulletIndent1"><span class="glyph">●</span>Intrinsic lung diseases, which cause inflammation or scarring of the lung tissue (interstitial lung disease) or fill the airspaces with exudate or debris (acute pneumonitis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extrinsic disorders, such as disorders of the chest wall or the pleura, which mechanically compress the lungs or limit their expansion</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neuromuscular disorders, which decrease the ability of the respiratory muscles to inflate and deflate the lungs</p><p></p><p>The history, physical examination, and chest radiograph are usually helpful in distinguishing among these disorders. Spirometry can be useful in detecting restriction of lung volumes, meaning a reduced FEV<sub>1</sub> and/or FVC with a normal or increased FEV<sub>1</sub>/FVC ratio. Evaluation of lung volumes and diffusing capacity are helpful in confirming the presence of restriction and assessing severity of impaired gas exchange  (<a class="graphic graphic_algorithm graphicRef96311" href="/d/graphic/96311.html" rel="external">algorithm 1</a>). However, patients with mild interstitial lung disease (ILD) may have normal values for FVC and TLC [<a href="#rid69">69</a>].</p><p>In ILD, the DLCO is decreased by diffuse alveolar capillary damage, and the measured alveolar volume (VA) is low due to the loss of aerated alveoli. The DLCO divided by alveolar volume (DLCO/VA, also known as KCO) is typically reduced to a lesser extent than the DLCO, as ILD is typically inhomogeneous with some diversion of blood flow from more diseased units to those that are less affected [<a href="#rid31">31,70</a>]. By comparison, in patients with restrictive physiology due to incomplete lung expansion (eg, neuromuscular disease or kyphoscoliosis), the DLCO is less decreased, and the reduction in DLCO is proportionately less than the reduction in VA, so the ratio DLCO/VA is actually increased. (See  <a class="medical medical_review" href="/d/html/6972.html" rel="external">"Diffusing capacity for carbon monoxide", section on 'Relationship between DLCO and KCO (DLCO/VA)'</a>.)</p><p>Changes in the FVC and DLCO are also useful for following the course of or response to therapy in patients with interstitial lung disease. Measurement of SpO<sub>2</sub> during a six-minute walk test (6MWT) is also useful in this setting, since SpO<sub>2</sub> often falls during mild exercise in patients with interstitial lung disease and responds to successful therapeutic interventions [<a href="#rid71">71</a>]. (See <a class="local">'Six-minute walk test'</a> above and  <a class="medical medical_review" href="/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing"</a>.)</p><p class="headingAnchor" id="H224258866"><span class="h2">Pulmonary vascular disease</span><span class="headingEndMark"> — </span>In pulmonary vascular disease (eg, thromboembolic disease or pulmonary arterial hypertension) not due to COPD or ILD, the DLCO is typically reduced due to impairment of gas exchange at the alveolar-capillary interface. Testing for desaturation with exercise oximetry can provide additional evidence of pulmonary vascular disease. (See  <a class="medical medical_review" href="/d/html/6972.html" rel="external">"Diffusing capacity for carbon monoxide", section on 'Interpretation'</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Preoperative testing</span><span class="headingEndMark"> — </span>Spirometry is useful for determining the risk of postoperative pulmonary complications in certain high-risk situations, including patients known to have COPD or asthma, current smokers, and those scheduled for thoracic or upper abdominal surgery [<a href="#rid72">72</a>]. The degree of airways obstruction predicts the risk of postoperative pulmonary complications, such as atelectasis, pneumonia, and the need for prolonged mechanical ventilation. If spirometry demonstrates moderate to severe obstruction and the surgery can be delayed, a prophylactic program of pulmonary hygiene, including smoking cessation, inhaled bronchodilators or glucocorticoids, and possibly antibiotics for bronchitis, will reduce the risk. However, the results of spirometry alone should not be used to deny surgery. Combining the results of spirometry with radioisotope or CT lung scans is also useful for predicting the remaining lung function following a lobectomy or pneumonectomy. (See  <a class="medical medical_review" href="/d/html/6917.html" rel="external">"Evaluation of perioperative pulmonary risk", section on 'Preoperative risk assessment'</a> and  <a class="medical medical_review" href="/d/html/6973.html" rel="external">"Preoperative physiologic pulmonary evaluation for lung resection"</a>.)</p><p>Evaluation of patients being considered for lung resection begins with spirometry and DLCO. If either of these tests is ≤80 percent of predicted, further testing is generally needed to calculate predicted postoperative lung function. A number of studies indicate that the maximum oxygen uptake (absolute value, or as a percent of predicted), determined by cardiopulmonary exercise testing, is better than spirometry for predicting postsurgical complications [<a href="#rid73">73</a>], but the cost:benefit ratio is unknown. (See  <a class="medical medical_review" href="/d/html/6973.html" rel="external">"Preoperative physiologic pulmonary evaluation for lung resection"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Respiratory impairment and disability assessment</span><span class="headingEndMark"> — </span>Most schemes for evaluation of respiratory impairment use spirometry and DLCO, but the results in studies performed at rest are only a rough indication of an individual's ability to perform a given job. It is ideal to measure maximal oxygen consumption (VO<sub>2</sub> max), but cardiopulmonary exercise testing is often not available to the primary care physicians who perform "disability" testing, or the expense is not reimbursed. (See  <a class="medical medical_review" href="/d/html/6966.html" rel="external">"Evaluation of pulmonary disability"</a>.)</p><p>The American Medical Association provides guidelines for the classification of respiratory impairment based upon the results of clinical evaluation, spirometry, DLCO, and cardiopulmonary exercise testing, if available. These guidelines are described separately. (See  <a class="medical medical_review" href="/d/html/6966.html" rel="external">"Evaluation of pulmonary disability", section on 'Calculating the permanent impairment rating'</a>.)</p><p>The Social Security Administration, Department of Veterans' Affairs in the United States, and United States Department of Labor have slightly different criteria for assessment of disability. (See  <a class="medical medical_review" href="/d/html/6966.html" rel="external">"Evaluation of pulmonary disability"</a> and  <a class="medical medical_review" href="/d/html/6966.html" rel="external">"Evaluation of pulmonary disability", section on 'Other systems'</a>.)</p><p class="headingAnchor" id="H3356600136"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118218.html" rel="external">"Society guideline links: Pulmonary function testing"</a>.)</p><p class="headingAnchor" id="H23269804"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/85379.html" rel="external">"Patient education: Breathing tests (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Pulmonary function testing is indicated for evaluation of respiratory symptoms (eg, cough, wheezing, dyspnea, chest pain), response to bronchodilator therapy, effect of workplace exposure to dust or chemicals, and pulmonary disability  (<a class="graphic graphic_algorithm graphicRef67095" href="/d/graphic/67095.html" rel="external">algorithm 3</a>). It can also be used to assess severity and progression of lung diseases, such as asthma, chronic obstructive lung disease, and various restrictive diseases. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">The major types of pulmonary function tests (PFTs) include spirometry, spirometry before and after bronchodilator, lung volumes, and diffusing capacity  (<a class="graphic graphic_table graphicRef106178" href="/d/graphic/106178.html" rel="external">table 1</a>). Other PFTs include flow-volume loops (which record forced inspiratory and expiratory flow rates), measurements of maximal respiratory pressures, and the six-minute walk test. (See <a class="local">'Pulmonary function tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spirometry</strong> – Forced expiratory volume in one second (FEV<sub>1</sub>) and forced vital capacity (FVC) are the primary measurements obtained by spirometry  (<a class="graphic graphic_algorithm graphicRef96311" href="/d/graphic/96311.html" rel="external">algorithm 1</a>). Their ratio (FEV<sub>1</sub>/FVC) is important for distinguishing obstructive airways disease and restrictive disease. A reduced ratio suggests obstructive airway disease. A reduced FVC in combination with a normal or increased ratio suggests restrictive disease, if accompanied by reduced lung volumes. (See <a class="local">'Spirometry'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flow-volume loops</strong> – Flow-volume loops with maximal inspiratory and expiratory data can identify upper airway obstruction, which can be undetectable with standard expiratory measurements. A characteristic limitation of flow (ie, a plateau) during forced inhalation suggests variable extrathoracic obstruction, while limitation of flow during forced exhalation suggests variable intrathoracic obstruction  (<a class="graphic graphic_figure graphicRef76811" href="/d/graphic/76811.html" rel="external">figure 1</a>). Fixed upper airway obstruction causes flow limitation during both forced inhalation and forced exhalation. (See  <a class="medical medical_review" href="/d/html/1465.html" rel="external">"Flow-volume loops"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchodilator response</strong> – When airflow limitation is noted on spirometry or when obstructive disease is suspected, the test is repeated after inhaled bronchodilator to detect bronchodilator responsiveness. An increase in the FEV<sub>1</sub> or FVC of more than 10 percent of their respective predicted values suggests bronchodilator responsiveness; full return to normal values for FEV<sub>1</sub> and FEV<sub>1</sub>/FVC suggests asthma. Partial improvement is consistent with asthma, COPD, or bronchiolitis. The lack of a bronchodilator response should not preclude a therapeutic trial of bronchodilators and/or inhaled glucocorticoids. (See <a class="local">'Post-bronchodilator'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung volumes</strong> – Measurement of lung volumes complements spirometry  (<a class="graphic graphic_algorithm graphicRef96311" href="/d/graphic/96311.html" rel="external">algorithm 1</a>). Common measurements include total lung capacity (TLC), functional residual capacity (FRC), and residual volume (RV)  (<a class="graphic graphic_figure graphicRef55440" href="/d/graphic/55440.html" rel="external">figure 2</a>). Decreased lung volumes suggest restrictive disease if accompanied by a normal or increased FEV<sub>1</sub>/FVC ratio. Increased lung volumes suggest static hyperinflation due to obstructive airways disease if accompanied by decreased FEV<sub>1</sub>/FVC ratio. Coexisting restriction and obstruction can be identified when the TLC and FEV<sub>1</sub>/FVC ratio are reduced. (See <a class="local">'Lung volumes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tests of muscle strength</strong> – Measurement of maximal inspiratory and expiratory pressures detects respiratory muscle weakness. Maximal inspiratory pressure (MIP) is the maximal pressure that can be produced by the patient trying to inhale through a blocked mouthpiece. Maximal expiratory pressure (MEP) is the maximal pressure measured during forced expiration through a blocked mouthpiece after a full inhalation. (See <a class="local">'Maximal respiratory pressures'</a> above and  <a class="medical medical_review" href="/d/html/6965.html" rel="external">"Tests of respiratory muscle strength"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffusing capacity of the lung for carbon monoxide (DLCO)</strong> – Measurement of DLCO assesses gas exchange. A decreased DLCO accompanied by restrictive disease suggests intrinsic lung disease, whereas a normal DLCO accompanied by restrictive disease suggests a nonpulmonary cause of restriction. A decreased DLCO accompanied by obstructive airways disease suggests emphysema. A reduced DLCO with normal lung volumes suggests possible pulmonary vascular disease  (<a class="graphic graphic_table graphicRef73588" href="/d/graphic/73588.html" rel="external">table 2</a>). (See <a class="local">'Diffusing capacity'</a> above and  <a class="medical medical_review" href="/d/html/6972.html" rel="external">"Diffusing capacity for carbon monoxide"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Grading physiologic impairment</strong> – Physiologic impairment should preferably be assessed based on z-score, instead of percent predicted value, because this scale helps avoid age, sex, and height bias and is closely associated with important clinical outcomes. FEV<sub>1</sub> is the primary measure used to grade the physiologic severity of obstructive or mixed obstructive-restrictive processes  (<a class="graphic graphic_algorithm graphicRef139645" href="/d/graphic/139645.html" rel="external">algorithm 2</a>). We prefer to use TLC z-score to grade severity of restriction; however, FEV<sub>1</sub> may be used as an alternative to grade previously confirmed restriction if lung volumes or z-scores are not available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Submaximal exercise tests</strong> – Submaximal exercise testing can help in the evaluation of dyspnea and exercise intolerance. Three commonly used tests are the six-minute walk test (6MWT), the incremental shuttle walk test, and the endurance shuttle walk test. The 6MWT provides information about the distance walked and exertional desaturation when combined with pulse oximetry  (<a class="graphic graphic_table graphicRef90285" href="/d/graphic/90285.html" rel="external">table 4</a>). (See <a class="local">'Submaximal exercise testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulse oxygen saturation (SpO</strong><strong><sub>2</sub></strong><strong>)</strong> – Assessment of SpO<sub>2</sub> at rest or with exertion can be used to identify a gas exchange defect and to titrate the amount of oxygen needed to maintain adequate oxygenation. A clear consensus has not been reached about the value for resting oximetry that differentiates normal and abnormal. At sea level, values for SpO<sub>2</sub> ≤95 percent are generally considered abnormal, although a decrease to 96 percent in a patient who has a previous value of 100 percent could be abnormal. Exertional decreases in SpO<sub>2</sub> ≥5 percentage points are also considered abnormal. (See <a class="local">'Pulse oxygen saturation'</a> above and  <a class="medical medical_review" href="/d/html/1612.html" rel="external">"Pulse oximetry"</a>.)</p><p></p><p class="headingAnchor" id="H21898629"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Paul Enright, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Crapo RO. Pulmonary-function testing. N Engl J Med 1994; 331:25.</a></li><li><a class="nounderline abstract_t">Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26:948.</a></li><li><a class="nounderline abstract_t">Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022; 60.</a></li><li><a class="nounderline abstract_t">Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014; 44:1428.</a></li><li><a class="nounderline abstract_t">Bhakta NR, McGowan A, Ramsey KA, et al. European Respiratory Society/American Thoracic Society technical statement: standardisation of the measurement of lung volumes, 2023 update. Eur Respir J 2023; 62.</a></li><li><a class="nounderline abstract_t">Graham BL, Steenbruggen I, Miller MR, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med 2019; 200:e70.</a></li><li><a class="nounderline abstract_t">Graham BL, Brusasco V, Burgos F, et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J 2017; 49.</a></li><li><a class="nounderline abstract_t">Coates AL, Wanger J, Cockcroft DW, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J 2017; 49.</a></li><li><a class="nounderline abstract_t">Hallstrand TS, Leuppi JD, Joos G, et al. ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing. Eur Respir J 2018; 52.</a></li><li><a class="nounderline abstract_t">Laveneziana P, Albuquerque A, Aliverti A, et al. ERS statement on respiratory muscle testing at rest and during exercise. Eur Respir J 2019; 53.</a></li><li class="breakAll">American Thoracic Society. Pulmonary Function Laboratories: Advice Regarding COVID-19. https://www.thoracic.org/professionals/clinical-resources/disease-related-resources/pulmonary-function-laboratories.php (Accessed on March 31, 2020).</li><li><a class="nounderline abstract_t">Wilson KC, Kaminsky DA, Michaud G, et al. Restoring Pulmonary and Sleep Services as the COVID-19 Pandemic Lessens. From an Association of Pulmonary, Critical Care, and Sleep Division Directors and American Thoracic Society-coordinated Task Force. Ann Am Thorac Soc 2020; 17:1343.</a></li><li class="breakAll">Recommendation from ERS Group 9.1 (Respiratory function technologists/Scientists): Lung function testing during COVID-19 pandemic and beyond. https://ers.app.box.com/s/zs1uu88wy51monr0ewd990itoz4tsn2h (Accessed on April 07, 2021).</li><li class="breakAll">British Thoracic Society: Respiratory Function Testing During Endemic COVID-19. https://www.artp.org.uk/write/MediaUploads/Standards/COVID19/Respiratory_Function_Testing_During_Endemic_COVID_V1.5.pdf (Accessed on April 07, 2021).</li><li><a class="nounderline abstract_t">Li J, Jing G, Fink JB, et al. Airborne Particulate Concentrations During and After Pulmonary Function Testing. Chest 2021; 159:1570.</a></li><li><a class="nounderline abstract_t">McGowan A, Laveneziana P, Bayat S, et al. International consensus on lung function testing during the COVID-19 pandemic and beyond. ERJ Open Res 2022; 8.</a></li><li><a class="nounderline abstract_t">Culver BH, Graham BL, Coates AL, et al. Recommendations for a Standardized Pulmonary Function Report. An Official American Thoracic Society Technical Statement. Am J Respir Crit Care Med 2017; 196:1463.</a></li><li><a class="nounderline abstract_t">Aaron SD, Dales RE, Cardinal P. How accurate is spirometry at predicting restrictive pulmonary impairment? Chest 1999; 115:869.</a></li><li><a class="nounderline abstract_t">Ward H, Cooper BG, Miller MR. Improved criterion for assessing lung function reversibility. Chest 2015; 148:877.</a></li><li><a class="nounderline abstract_t">Tan WC, Vollmer WM, Lamprecht B, et al. Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study. Thorax 2012; 67:718.</a></li><li><a class="nounderline abstract_t">Barjaktarevic IZ, Buhr RG, Wang X, et al. Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis. Int J Chron Obstruct Pulmon Dis 2019; 14:2927.</a></li><li><a class="nounderline abstract_t">Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008; 31:742.</a></li><li><a class="nounderline abstract_t">O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:542.</a></li><li><a class="nounderline abstract_t">Modrykamien AM, Gudavalli R, McCarthy K, et al. Detection of upper airway obstruction with spirometry results and the flow-volume loop: a comparison of quantitative and visual inspection criteria. Respir Care 2009; 54:474.</a></li><li><a class="nounderline abstract_t">Stănescu DC, Rodenstein D, Cauberghs M, Van de Woestijne KP. Failure of body plethysmography in bronchial asthma. J Appl Physiol Respir Environ Exerc Physiol 1982; 52:939.</a></li><li><a class="nounderline abstract_t">Washko GR, Hunninghake GM, Fernandez IE, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 2011; 364:897.</a></li><li><a class="nounderline abstract_t">Hyatt RE, Cowl CT, Bjoraker JA, Scanlon PD. Conditions associated with an abnormal nonspecific pattern of pulmonary function tests. Chest 2009; 135:419.</a></li><li><a class="nounderline abstract_t">Clay RD, Iyer VN, Reddy DR, et al. The "Complex Restrictive" Pulmonary Function Pattern: Clinical and Radiologic Analysis of a Common but Previously Undescribed Restrictive Pattern. Chest 2017; 152:1258.</a></li><li><a class="nounderline abstract_t">Bruschi C, Cerveri I, Zoia MC, et al. Reference values of maximal respiratory mouth pressures: a population-based study. Am Rev Respir Dis 1992; 146:790.</a></li><li><a class="nounderline abstract_t">Enright PL, Kronmal RA, Manolio TA, et al. Respiratory muscle strength in the elderly. Correlates and reference values. Cardiovascular Health Study Research Group. Am J Respir Crit Care Med 1994; 149:430.</a></li><li><a class="nounderline abstract_t">Hughes JM, Pride NB. Examination of the carbon monoxide diffusing capacity (DL(CO)) in relation to its KCO and VA components. Am J Respir Crit Care Med 2012; 186:132.</a></li><li><a class="nounderline abstract_t">Miller MR, Cooper BG. Reduction in TLCO and survival in a clinical population. Eur Respir J 2021; 58.</a></li><li><a class="nounderline abstract_t">Quanjer PH, Pretto JJ, Brazzale DJ, Boros PW. Grading the severity of airways obstruction: new wine in new bottles. Eur Respir J 2014; 43:505.</a></li><li><a class="nounderline abstract_t">Singh SJ, Puhan MA, Andrianopoulos V, et al. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J 2014; 44:1447.</a></li><li><a class="nounderline abstract_t">Enright PL. The six-minute walk test. Respir Care 2003; 48:783.</a></li><li><a class="nounderline abstract_t">Swigris JJ, Wamboldt FS, Behr J, et al. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010; 65:173.</a></li><li><a class="nounderline abstract_t">Swigris JJ, Olson AL, Shlobin OA, et al. Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology 2011; 16:439.</a></li><li><a class="nounderline abstract_t">Casanova C, Celli BR, Barria P, et al. The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur Respir J 2011; 37:150.</a></li><li><a class="nounderline abstract_t">Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997; 155:1278.</a></li><li><a class="nounderline abstract_t">du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183:1231.</a></li><li><a class="nounderline abstract_t">Holland AE, Hill CJ, Conron M, et al. Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. Respir Med 2009; 103:1430.</a></li><li><a class="nounderline abstract_t">Mathai SC, Puhan MA, Lam D, Wise RA. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186:428.</a></li><li><a class="nounderline abstract_t">Gilbert C, Brown MC, Cappelleri JC, et al. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest 2009; 135:137.</a></li><li><a class="nounderline abstract_t">Puhan MA, Chandra D, Mosenifar Z, et al. The minimal important difference of exercise tests in severe COPD. Eur Respir J 2011; 37:784.</a></li><li><a class="nounderline abstract_t">Puhan MA, Mador MJ, Held U, et al. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J 2008; 32:637.</a></li><li><a class="nounderline abstract_t">Wise RA, Brown CD. Minimal clinically important differences in the six-minute walk test and the incremental shuttle walking test. COPD 2005; 2:125.</a></li><li><a class="nounderline abstract_t">Parreira VF, Janaudis-Ferreira T, Evans RA, et al. Measurement properties of the incremental shuttle walk test. a systematic review. Chest 2014; 145:1357.</a></li><li><a class="nounderline abstract_t">Probst VS, Hernandes NA, Teixeira DC, et al. Reference values for the incremental shuttle walking test. Respir Med 2012; 106:243.</a></li><li><a class="nounderline abstract_t">Harrison SL, Greening NJ, Houchen-Wolloff L, et al. Age-specific normal values for the incremental shuttle walk test in a healthy British population. J Cardiopulm Rehabil Prev 2013; 33:309.</a></li><li><a class="nounderline abstract_t">Singh SJ, Morgan MD, Scott S, et al. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992; 47:1019.</a></li><li><a class="nounderline abstract_t">Singh SJ, Jones PW, Evans R, Morgan MD. Minimum clinically important improvement for the incremental shuttle walking test. Thorax 2008; 63:775.</a></li><li><a class="nounderline abstract_t">Win T, Jackson A, Groves AM, et al. Comparison of shuttle walk with measured peak oxygen consumption in patients with operable lung cancer. Thorax 2006; 61:57.</a></li><li><a class="nounderline abstract_t">Revill SM, Morgan MD, Singh SJ, et al. The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. Thorax 1999; 54:213.</a></li><li><a class="nounderline abstract_t">Singh SJ, Morgan MD, Hardman AE, et al. Comparison of oxygen uptake during a conventional treadmill test and the shuttle walking test in chronic airflow limitation. Eur Respir J 1994; 7:2016.</a></li><li><a class="nounderline abstract_t">Long-Term Oxygen Treatment Trial Research Group, Albert RK, Au DH, et al. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med 2016; 375:1617.</a></li><li><a class="nounderline abstract_t">Feiner JR, Severinghaus JW, Bickler PE. Dark skin decreases the accuracy of pulse oximeters at low oxygen saturation: the effects of oximeter probe type and gender. Anesth Analg 2007; 105:S18.</a></li><li><a class="nounderline abstract_t">van der Molen T, Østrem A, Stallberg B, et al. International Primary Care Respiratory Group (IPCRG) Guidelines: management of asthma. Prim Care Respir J 2006; 15:35.</a></li><li><a class="nounderline abstract_t">Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. Chest 2000; 117:1146.</a></li><li><a class="nounderline abstract_t">Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155:179.</a></li><li><a class="nounderline abstract_t">Miller MR, Quanjer PH, Swanney MP, et al. Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. Chest 2011; 139:52.</a></li><li><a class="nounderline abstract_t">Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008; 63:1046.</a></li><li><a class="nounderline abstract_t">Bhatt SP, Balte PP, Schwartz JE, et al. Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality. JAMA 2019; 321:2438.</a></li><li><a class="nounderline abstract_t">Dykstra BJ, Scanlon PD, Kester MM, et al. Lung volumes in 4,774 patients with obstructive lung disease. Chest 1999; 115:68.</a></li><li><a class="nounderline abstract_t">Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161:381.</a></li><li><a class="nounderline abstract_t">Kohansal R, Martinez-Camblor P, Agustí A, et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 2009; 180:3.</a></li><li><a class="nounderline abstract_t">Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153:1530.</a></li><li><a class="nounderline abstract_t">Leach RM, Davidson AC, Chinn S, et al. Portable liquid oxygen and exercise ability in severe respiratory disability. Thorax 1992; 47:781.</a></li><li><a class="nounderline abstract_t">Balasubramanian A, MacIntyre NR, Henderson RJ, et al. Diffusing Capacity of Carbon Monoxide in Assessment of COPD. Chest 2019; 156:1111.</a></li><li><a class="nounderline abstract_t">Boros PW, Enright PL, Quanjer PH, et al. Impaired lung compliance and DL,CO but no restrictive ventilatory defect in sarcoidosis. Eur Respir J 2010; 36:1315.</a></li><li><a class="nounderline abstract_t">Kanengiser LC, Rapoport DM, Epstein H, Goldring RM. Volume adjustment of mechanics and diffusion in interstitial lung disease. Lack of clinical relevance. Chest 1989; 96:1036.</a></li><li><a class="nounderline abstract_t">Hadeli KO, Siegel EM, Sherrill DL, et al. Predictors of oxygen desaturation during submaximal exercise in 8,000 patients. Chest 2001; 120:88.</a></li><li><a class="nounderline abstract_t">Zibrak JD, O'Donnell CR, Marton K. Indications for pulmonary function testing. Ann Intern Med 1990; 112:763.</a></li><li><a class="nounderline abstract_t">Olsen GN. The evolving role of exercise testing prior to lung resection. Chest 1989; 95:218.</a></li></ol></div><div id="topicVersionRevision">Topic 6969 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8202099" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pulmonary-function testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16264058" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Interpretative strategies for lung function tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34949706" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : ERS/ATS technical standard on interpretive strategies for routine lung function tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25359355" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37500112" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : European Respiratory Society/American Thoracic Society technical statement: standardisation of the measurement of lung volumes, 2023 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31613151" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28049168" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28461290" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30361249" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30956204" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ERS statement on respiratory muscle testing at rest and during exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30956204" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : ERS statement on respiratory muscle testing at rest and during exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32663071" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Restoring Pulmonary and Sleep Services as the COVID-19 Pandemic Lessens. From an Association of Pulmonary, Critical Care, and Sleep Division Directors and American Thoracic Society-coordinated Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32663071" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Restoring Pulmonary and Sleep Services as the COVID-19 Pandemic Lessens. From an Association of Pulmonary, Critical Care, and Sleep Division Directors and American Thoracic Society-coordinated Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32663071" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Restoring Pulmonary and Sleep Services as the COVID-19 Pandemic Lessens. From an Association of Pulmonary, Critical Care, and Sleep Division Directors and American Thoracic Society-coordinated Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33144080" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Airborne Particulate Concentrations During and After Pulmonary Function Testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35261912" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : International consensus on lung function testing during the COVID-19 pandemic and beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29192835" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Recommendations for a Standardized Pulmonary Function Report. An Official American Thoracic Society Technical Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084506" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : How accurate is spirometry at predicting restrictive pulmonary impairment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25879725" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Improved criterion for assessing lung function reversibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22544896" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31908441" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18256071" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bronchodilator responsiveness in patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430726" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19327182" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Detection of upper airway obstruction with spirometry results and the flow-volume loop: a comparison of quantitative and visual inspection criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7085427" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Failure of body plethysmography in bronchial asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21388308" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Lung volumes and emphysema in smokers with interstitial lung abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18812444" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Conditions associated with an abnormal nonspecific pattern of pulmonary function tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28728932" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The "Complex Restrictive" Pulmonary Function Pattern: Clinical and Radiologic Analysis of a Common but Previously Undescribed Restrictive Pattern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1519865" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Reference values of maximal respiratory mouth pressures: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8306041" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Respiratory muscle strength in the elderly. Correlates and reference values. Cardiovascular Health Study Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22538804" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Examination of the carbon monoxide diffusing capacity (DL(CO)) in relation to its KCO and VA components.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33863741" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Reduction in TLCO and survival in a clinical population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23988764" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Grading the severity of airways obstruction: new wine in new bottles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25359356" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12890299" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The six-minute walk test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996335" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20946337" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20525717" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The 6-min walk distance in healthy subjects: reference standards from seven countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9105067" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21131468" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19477109" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Small changes in six-minute walk distance are important in diffuse parenchymal lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22723290" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18812447" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20693247" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The minimal important difference of exercise tests in severe COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18550610" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Interpretation of treatment changes in 6-minute walk distance in patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17136972" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Minimal clinically important differences in the six-minute walk test and the incremental shuttle walking test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24384555" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Measurement properties of the incremental shuttle walk test. a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21865021" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Reference values for the incremental shuttle walking test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23959208" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Age-specific normal values for the incremental shuttle walk test in a healthy British population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1494764" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Development of a shuttle walking test of disability in patients with chronic airways obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18390634" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Minimum clinically important improvement for the incremental shuttle walking test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16244091" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Comparison of shuttle walk with measured peak oxygen consumption in patients with operable lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10325896" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7875275" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Comparison of oxygen uptake during a conventional treadmill test and the shuttle walking test in chronic airflow limitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27783918" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18048893" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Dark skin decreases the accuracy of pulse oximeters at low oxygen saturation: the effects of oximeter probe type and gender.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16701757" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : International Primary Care Respiratory Group (IPCRG) Guidelines: management of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10767253" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21810710" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20522571" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18786983" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31237643" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9925064" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Lung volumes in 4,774 patients with obstructive lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673175" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19342411" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630597" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1481177" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Portable liquid oxygen and exercise ability in severe respiratory disability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31352035" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Diffusing Capacity of Carbon Monoxide in Assessment of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20378598" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Impaired lung compliance and DL,CO but no restrictive ventilatory defect in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2805833" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Volume adjustment of mechanics and diffusion in interstitial lung disease. Lack of clinical relevance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11451821" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Predictors of oxygen desaturation during submaximal exercise in 8,000 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2139550" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Indications for pulmonary function testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2642409" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The evolving role of exercise testing prior to lung resection.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
